The Food and Drug Administration (FDA or the Agency) is announcing the following public workshop entitled "Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop." The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives. FDA is seeking this input from a variety of interested parties--industry, academia, patient advocates, professional societies, and o

Original title: “Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments”

In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Office of Extramural Research (OER), in the Office of the Director (OD), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Original title: “Submission for OMB Review; 30-Day Comment Request; A Generic Submission for Formative Research, Pilot Testing, Pretesting and Customer Satisfaction of NIH Communication and Education Resources (OD/OER)”

Referred to the House Committee on Financial Services.

Original title: “HR 7701: To amend the United States Housing Act of 1937 to reduce rent in public housing for police officers, firefighters, and emergency medical technicians.”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 6509: SAFE Drugs Act of 2025”

Referred to the Subcommittee on Health.

Original title: “HR 3489: Department of Veterans Affairs Medical Physicist Pay Cap Relief Act”

Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including around specific evidence required for the single study and why it hasn’t been implemented across all therapeutic areas before now.

Original title: “FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 3922: A bill to amend the Federal Food, Drug, and Cosmetic Act to clarify the Food and Drug Administration's jurisdiction over certain tobacco products, and to protect jobs and small businesses involved in the sale, manufacturing, and distribution of traditional and premium cigars.”

Read twice and referred to the Committee on Finance.

Original title: “S 3159: A bill to amend title XVIII of the Social Security Act to temporarily provide for long-term care pharmacy supply fees in connection with the dispensing of certain drugs.”

Read twice and referred to the Committee on Veterans' Affairs.

Original title: “S 1726: A bill to amend title 38, United States Code, to clarify that the Department of Veterans Affairs definition of "medical services" includes medically necessary automobile adaptations, and for other purposes.”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 1716: A bill to amend title XXVII of the Public Health Service Act to improve health care coverage under vision plans, and for other purposes.”

Read twice and referred to the Committee on Finance.

Original title: “S 1183: A bill to amend the Internal Revenue Code of 1986 to support upgrades at existing hydroelectric dams in order to increase clean energy production, improve the resiliency and reliability of the United States electric grid, enhance the health of the Nation's rivers and associated wildlife habitats, and for other purposes.”

Read twice and referred to the Committee on the Judiciary.

Original title: “S 709: A bill to provide incentives to physicians to practice in rural and medically underserved communities, and for other purposes.”

Read twice and referred to the Committee on Finance.

Original title: “S 3834: Expanded Telehealth Access Act”

Certain actions can increase your risk of getting botulism.

Original title: “People at Increased Risk for Botulism”

Learn how to lower your cancer risk and what CDC is doing to prevent and control cancer.

Original title: “Cancer”

Flu is a contagious respiratory illness that infect the nose, throat, and sometimes the lungs.

Original title: “About Influenza”

This page describes how to prevent various types of botulism.

Original title: “Botulism Prevention”

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MERIT MEDICAL WRAPSODY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.

Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; MERIT MEDICAL WRAPSODY”

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRYNGOLZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; TRYNGOLZA”

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AEROPACE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.

Original title: “Determination of Regulatory Review Period for Purposes of Patent Extension; AEROPACE”